{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T18:28:42Z","timestamp":1759775322060},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T00:00:00Z","timestamp":1689120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T00:00:00Z","timestamp":1689120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002999","name":"Dutch Ministry of Health, Welfare and Sport","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002999","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Sanquin \u2018Product and Process Development - Cellular Products\u2019","award":["PPOC20-01"],"award-info":[{"award-number":["PPOC20-01"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) booster vaccination campaign and the emergence of SARS-CoV-2 Omicron variants impact the prevalence and levels of SARS-CoV-2 antibodies in the Netherlands. In this study we determined antibody levels across age groups, the impact of Omicron variant infections, and the effect of booster vaccinations on antibody levels.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In September and December 2021 and in February 2022, over 2000 Dutch blood donors were tested for presence of SARS-CoV-2 antibodies. Donations were selected based on age, sex, and region of residence, to provide an optimal coverage and representation of the Dutch population.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Levels of vaccination-induced spike antibodies decreased over time in all age groups. Donors vaccinated with Janssen or AstraZeneca had significantly lower antibody levels than donors vaccinated with Pfizer or Moderna vaccine. Boostering with an mRNA vaccine elevated antibody levels in all age-groups irrespective of the initial vaccine. In donors aged\u2009&lt;\u200956 years, the proportion of infected donors almost doubled between December 2021 and February 2022.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The booster vaccination campaign increased antibody levels in all age-groups. After a booster vaccination, donors initially vaccinated with AstraZeneca or Janssen vaccine showed antibody levels similar to donors initially vaccinated with an mRNA vaccine. The emergence of the SARS-CoV-2 Omicron variant in the Netherlands caused a substantial increase in donors with infection-induced antibodies, especially among younger donors.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-023-08448-w","type":"journal-article","created":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T15:02:18Z","timestamp":1689174138000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Booster vaccinations and Omicron: the effects on SARS-CoV-2 antibodies in Dutch blood donors"],"prefix":"10.1186","volume":"23","author":[{"given":"F. A.","family":"Quee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. M.","family":"Hogema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Slot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Kruijer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Molier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"van den Hurk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. L.","family":"Zaaijer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,12]]},"reference":[{"key":"8448_CR1","doi-asserted-by":"crossref","unstructured":"Wu F, Zhao S, Yu B, Chen Y-M, Wang W, Song Z-G et al. A new coronavirus associated with human respiratory disease in China. Nat 2020 Mar;579(7798):265\u20139.","DOI":"10.1038\/s41586-020-2008-3"},{"key":"8448_CR2","doi-asserted-by":"crossref","unstructured":"Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with Pneumonia in China, 2019. N Engl J Med. 2020 Feb;382(8):727\u201333.","DOI":"10.1056\/NEJMoa2001017"},{"key":"8448_CR3","unstructured":"RIVM. Epidemiologische situatie van SARS-CoV-2 in Nederland [Internet]. Rijksinstituut voor Volksgezondheid en Milieu. ; 2021. Available from: https:\/\/www.rivm.nl\/coronavirus-covid-19\/actueel\/wekelijkse-update-epidemiologische-situatie-covid-19-in-nederland."},{"key":"8448_CR4","doi-asserted-by":"crossref","unstructured":"Kl\u00e4ser K, Molteni E, Graham M, Canas LS, \u00d6sterdahl MF, Antonelli M, et al. COVID-19 due to the B.1.617.2 (Delta) variant compared to B.1.1.7 (alpha) variant of SARS-CoV-2: a prospective observational cohort study. Sci Rep. 2022 Jun;12(1):10904.","DOI":"10.1101\/2021.11.24.21266748"},{"key":"8448_CR5","doi-asserted-by":"publisher","unstructured":"Ong SWX, Chiew CJ, Ang LW, Mak TM, Cui L, Toh MPHS et al. Clinical and Virological Features of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern: A Retrospective Cohort Study Comparing B.1.1.7 (Alpha), B.1.351 (Beta), and B.1.617.2 (Delta). Clin Infect Dis [Internet]. 2022 Jul 1;75(1):e1128\u201336. Available from: https:\/\/doi.org\/10.1093\/cid\/ciab721.","DOI":"10.1093\/cid\/ciab721"},{"issue":"3","key":"8448_CR6","doi-asserted-by":"publisher","first-page":"e699","DOI":"10.1093\/cid\/ciab004","volume":"73","author":"SF Lumley","year":"2021","unstructured":"Lumley SF, Wei J, O\u2019Donnell D, Stoesser NE, Matthews PC, Howarth A, et al. The Duration, Dynamics, and determinants of severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) antibody responses in Individual Healthcare Workers. Clin Infect Dis. 2021;73(3):e699\u2013709. 2021\/01\/06.","journal-title":"Clin Infect Dis"},{"key":"8448_CR7","unstructured":"RIVM. Wekelijkse update deelname COVID-19 vaccinatie in Nederland [Internet]. 2022. Available from: https:\/\/www.rivm.nl\/covid-19-vaccinatie\/wekelijkse-update-deelname-covid-19-vaccinatie-in-nederland."},{"key":"8448_CR8","unstructured":"O WH. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern [Internet]. 2021. Available from: https:\/\/www.who.int\/news\/item\/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern."},{"key":"8448_CR9","doi-asserted-by":"crossref","unstructured":"Espenhain L, Funk T, Overvad M, Edslev SM, Fonager J, Ingham AC et al. Epidemiological characterisation of the first 785 SARS-CoV-2 Omicron variant cases in Denmark, December 2021. Euro Surveill. 2021\/12\/18. 2021;26(50).","DOI":"10.2807\/1560-7917.ES.2021.26.50.2101146"},{"issue":"7898","key":"8448_CR10","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41586-021-04385-3","volume":"602","author":"Y Cao","year":"2022","unstructured":"Cao Y, Wang J, Jian F, Xiao T, Song W, Yisimayi A, et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nat 2022\/01\/12. 2022;602(7898):657\u201363.","journal-title":"Nat 2022\/01\/12"},{"key":"8448_CR11","doi-asserted-by":"crossref","unstructured":"Eggink D, Andeweg SP, Vennema H, van Maarseveen N, Vermaas K, Vlaemynck B et al. Increased risk of infection with SARS-CoV-2 Omicron BA.1 compared with Delta in vaccinated and previously infected individuals, the Netherlands, 22 November 2021 to 19 January 2022. Euro Surveill. 2022\/01\/29. 2022;27(4).","DOI":"10.2807\/1560-7917.ES.2022.27.4.2101196"},{"key":"8448_CR12","doi-asserted-by":"crossref","unstructured":"Kiss Z, Wittmann I, Polivka L, Surj\u00e1n G, Surj\u00e1n O, Barcza Z et al. Nationwide Effectiveness of First and Second SARS-CoV2 Booster Vaccines During the Delta and Omicron Pandemic Waves in Hungary (HUN-VE 2 Study). Front Immunol. 2022\/07\/12. 2022;13:905585.","DOI":"10.3389\/fimmu.2022.905585"},{"key":"8448_CR13","unstructured":"Sanquin. Bloeddonors in Nederland [Internet]. 2022. Available from: https:\/\/www.sanquin.nl\/bloed-doneren\/bloeddonoren-in-nederland."},{"key":"8448_CR14","unstructured":"CBS. Bevolking; geslacht, leeftijd en burgerlijke staat, 1 januari. [Internet]. 2021. Available from: https:\/\/opendata.cbs.nl\/statline\/#\/CBS\/nl\/dataset\/7461BEV\/table?fromstatweb."},{"key":"8448_CR15","unstructured":"Serology Taskforce part of the DNTCCS. Status of the validation of ELISA and autoanalyser antibody tests for SARS-CoV-2 diagnostics: considerations for use. 2020; Available from: https:\/\/www.rivm.nl\/sites\/default\/files\/2020-07\/Status validation ELISA and auto-analysers 2020715.pdf."},{"key":"8448_CR16","doi-asserted-by":"crossref","unstructured":"Shrotri M, Fragaszy E, Nguyen V, Navaratnam AMD, Geismar C, Beale S, et al. Spike-antibody responses to COVID-19 vaccination by demographic and clinical factors in a prospective community cohort study. Nat Commun. 2022 Oct;13(1):5780.","DOI":"10.1038\/s41467-022-33550-z"},{"key":"8448_CR17","doi-asserted-by":"crossref","unstructured":"Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E et al. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. N Engl J Med. 2022\/03\/07. 2022;386(16):1532\u201346.","DOI":"10.1056\/NEJMoa2119451"},{"key":"8448_CR18","doi-asserted-by":"crossref","unstructured":"Erikstrup C, Laksafoss AD, Gladov J, Kaspersen KA, Mikkelsen S, Hindhede L, et al. Seroprevalence and infection fatality rate of the SARS-CoV-2 Omicron variant in Denmark: a nationwide serosurveillance study. Lancet Reg Heal Eur. 2022 Oct;21:100479.","DOI":"10.1016\/j.lanepe.2022.100479"},{"key":"8448_CR19","doi-asserted-by":"publisher","unstructured":"ISBT 2022 - Abstract Book. Vox Sang [Internet]. 2022 Jun 1;117(S1):6\u2013271. Available from: https:\/\/doi.org\/10.1111\/vox.13285.","DOI":"10.1111\/vox.13285"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08448-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-023-08448-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08448-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T15:02:29Z","timestamp":1689174149000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-023-08448-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,12]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["8448"],"URL":"https:\/\/doi.org\/10.1186\/s12879-023-08448-w","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,12]]},"assertion":[{"value":"6 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Samples were collected only from voluntary, non-remunerated, adult donors who provided written informed consent as part of routine donor selection and blood collection procedures. The study was reviewed and approved by the Ethics Advisory Council of Sanquin Blood Supply Foundation. All methods were performed in accordance with the relevant guidelines and regulations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"464"}}